Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1728 |
| _version_ | 1797469738589224960 |
|---|---|
| author | Agata Błaszczuk Aleksander Michalski Dominika Sikora Maria Malm Bartłomiej Drop Małgorzata Polz-Dacewicz |
| author_facet | Agata Błaszczuk Aleksander Michalski Dominika Sikora Maria Malm Bartłomiej Drop Małgorzata Polz-Dacewicz |
| author_sort | Agata Błaszczuk |
| collection | DOAJ |
| description | The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies. |
| first_indexed | 2024-03-09T19:24:27Z |
| format | Article |
| id | doaj.art-f200d40d9d874fc9a8f73f6c9a6e77d1 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:24:27Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f200d40d9d874fc9a8f73f6c9a6e77d12023-11-24T03:05:01ZengMDPI AGVaccines2076-393X2022-10-011010172810.3390/vaccines10101728Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron VariantAgata Błaszczuk0Aleksander Michalski1Dominika Sikora2Maria Malm3Bartłomiej Drop4Małgorzata Polz-Dacewicz5Department of Virology with SARS Laboratory, Medical University of Lublin, 20-093 Lublin, Poland1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, PolandDepartment of Virology with SARS Laboratory, Medical University of Lublin, 20-093 Lublin, PolandDepartment of Computer Science and Medical Statistics with the e-Health Laboratory, 20-090 Lublin, PolandDepartment of Computer Science and Medical Statistics with the e-Health Laboratory, 20-090 Lublin, PolandDepartment of Virology with SARS Laboratory, Medical University of Lublin, 20-093 Lublin, PolandThe SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies.https://www.mdpi.com/2076-393X/10/10/1728SARS-CoV-2COVID-19SARS CoV-2 antibodyNCPRBDS2 |
| spellingShingle | Agata Błaszczuk Aleksander Michalski Dominika Sikora Maria Malm Bartłomiej Drop Małgorzata Polz-Dacewicz Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant Vaccines SARS-CoV-2 COVID-19 SARS CoV-2 antibody NCP RBD S2 |
| title | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
| title_full | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
| title_fullStr | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
| title_full_unstemmed | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
| title_short | Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant |
| title_sort | antibody response after sars cov 2 infection with the delta and omicron variant |
| topic | SARS-CoV-2 COVID-19 SARS CoV-2 antibody NCP RBD S2 |
| url | https://www.mdpi.com/2076-393X/10/10/1728 |
| work_keys_str_mv | AT agatabłaszczuk antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT aleksandermichalski antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT dominikasikora antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT mariamalm antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT bartłomiejdrop antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant AT małgorzatapolzdacewicz antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant |